Navigation Links
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Date:12/17/2007

one of two treatment arms:

-- Treatment arm A received dose-dense combination of doxorubicin and

cyclophosphamide with Avastin, followed by paclitaxel and Avastin,

followed by Avastin alone. Avastin was given every 2 weeks at a dose

of 10 mg/kg for 1 year.

-- Treatment arm B was only different to arm A in that Avastin was

introduced after completion of doxorubicin therapy in conjunction with

paclitaxel. As with arm A, patients remained on Avastin for 1 year

after Avastin initiation.

The primary objective of the study was to determine the incidence of clinically apparent cardiac dysfunction in patients with lymph node positive breast cancer treated with bevacizumab and dose dense doxorubicin/cyclophosphamide followed by paclitaxel (ddAC>T). Patients were evaluated clinically and with serial assessments of left ventricular function over the course of their treatment and for six months following treatment.

Additional information

-- Roche in Oncology:

http://www.roche.com/pages/downloads/company/pdf/mboncology05e_b.pdf

-- Roche Health Kiosk, Cancer:

http://www.health-kiosk.ch/start_krebs

References:

(1) Miller KD, et al. E2100 Breast Cancer Res Treat 2005;94:S6

(Abstract 3)

(2) Kamangar F, et al. J Clin Oncol 2006; 24(14): 2137-50.


'/>"/>
SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
2. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  CytRx Corporation (NASDAQ: CYTR ... oncology, today reported financial results for the three months ... of recent accomplishments and upcoming milestones for its clinical ... has been very productive for CytRx. Enrollment in our ... in soft tissue sarcoma (STS) continues on track to ...
(Date:8/3/2015)... 3, 2015  BioElectronics Corporation (OTC Pink: BIEL), maker ... that Andrew J. Whelan , President will be ... "On Business" at 9am EDT on Wednesday, August 5 ... to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... acceptance the company,s flagship product, ActiPatch Therapy, is achieving ...
(Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, ... will host its Second Quarter 2015 Investor Conference Call ...    The call will cover an update ... second quarter 2015 financials. A press release detailing the ... issued the afternoon of Monday, August 10. Investors and ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2
... Northwestern Memorial Hospital is one of six national participants ... lung cancer patients and their families have a smoother ... to reduce medical error and to reliably adhere to ... Commission on Cancer and the Society of Thoracic Surgeons ...
... PRUSSIA, Pa., Nov. 18, 2010  Prism ... & Drug Administration (FDA) has approved the supplemental ... Injection, the first and only premixed intravenous (IV) ...  NEXTERONE Premixed Injection is indicated for initiation of ...
Cached Medicine Technology:Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 2Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 3Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection 2Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection 3
(Date:8/3/2015)... ... , ... They know every second counts. And when it comes to stroke, ... the best care in the nation. For the past two months, the stroke team ... removal time in the country. During the months of June and July, it took ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B Awards ... brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics product was ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the ... to offer pharmacogenetic lab testing and precision medicine solutions that can help pharmacists ... , Annually, more than 8.6 million adverse drug events are reported in the ...
(Date:8/3/2015)... , ... August 03, 2015 ... ... and fitness site and the largest online retailer of nutritional supplements, has ... Sports is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2
... tips on controlling your flatulence , ... East Longmeadow, ... necessary. In fact, the average person passes gas about 14 times ... However, every body behaves differently and some experience more gas than ...
... Robert Bernstein, developer of the Follicular Unit Transplantation procedure for ... hair loss and its treatment. , ... ... The Oprah Winfrey Show features Dr. Bernstein discussing his pioneering ...
... previously published ACSM/AHA, guidelines, INDIANAPOLIS ... activity released today by the U.S. Department ... with support from the American College of,Sports ... (AHA). The,organizations, which jointly published physical activity ...
... ANAHEIM, Calif., Oct. 7 CHADD, ... by AD/HD, will hold its Annual,International ... Anaheim, California.,The conference will feature some ... variety,topics of interest to parents, adults, ...
... similar to more expensive whole-leg color ultrasound, study ... older, simpler test to look for blood clots in ... -- is as effective as a newer, more expensive ... 2-point ultrasonography of the leg -- sometimes called compression ...
... the University of California, San Diego (UCSD) in La Jolla ... lung cancer by treating patients with a novel kind of ... immune system to fight off a cancer, the new vaccine, ... turning off its immune system-suppressing activities. , The first patients ...
Cached Medicine News:Health News:Managing Gas Isn't Rocket Science 2Health News:Managing Gas Isn't Rocket Science 3Health News:Pioneering Hair Transplant Doctor Explains Procedure on Oprah Winfrey Show 2Health News:ACSM, AHA Support Federal Physical Activity Guidelines 2Health News:ACSM, AHA Support Federal Physical Activity Guidelines 3Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3Health News:Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center 2
... AccuGENE Molecular Biology Buffers are ready-to-use ... molecular biology applications. Each reagent is prepared ... 0.2 micron filter, and filled into sterile ... strict quality control standards to ensure lot-to-lot ...
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
Medicine Products: